We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,523 hedge funds and large institutions have $63.3B invested in Bristol-Myers Squibb in 2016 Q3 according to their latest regulatory filings, with 110 funds opening new positions, 663 increasing their positions, 548 reducing their positions, and 147 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 663 | Existing positions reduced: 548

3.14% less ownership

Funds ownership: 73.94%70.8% (-3.1%)

3% less funds holding

Funds holding: 1,5771,523 (-54)

17% less call options, than puts

Call options by funds: $1.15B | Put options by funds: $1.38B

25% less first-time investments, than exits

New positions opened: 110 | Existing positions closed: 147

30% less capital invested

Capital invested by funds: $90.9B → $63.3B (-$27.6B)

55% less funds holding in top 10

Funds holding in top 10: 11049 (-61)

Holders
1,523
Holders Change
-54
Holders Change %
-3.42%
% of All Funds
40.62%
Holding in Top 10
49
Holding in Top 10 Change
-61
Holding in Top 10 Change %
-55.45%
% of All Funds
1.31%
New
110
Increased
663
Reduced
548
Closed
147
Calls
$1.15B
Puts
$1.38B
Net Calls
-$227M
Net Calls Change
-$366M
Name Holding Trade Value Shares
Change
Change in
Stake
BIA
401
Biondo Investment Advisors
Pennsylvania
$6.79M +$71.5K +1,113 +0.9%
TCM
402
Tufton Capital Management
Maryland
$6.79M +$1.9M +29,606 +31%
GL
403
GLG LLC
New York
$6.76M -$999K -15,554 -11%
CIC
404
Cutler Investment Counsel
Oregon
$6.66M +$73.2K +1,139 +0.9%
BT
405
Beacon Trust
New Jersey
$6.66M -$690K -10,738 -8%
DL
406
Delta Lloyd
Netherlands
$6.59M +$662K +10,306 +9%
Two Sigma Investments
407
Two Sigma Investments
New York
$6.57M +$7.49M +116,551 +2,181%
GJIC
408
Gamble Jones Investment Counsel
California
$6.53M -$155K -2,416 -2%
OPCM
409
Osborne Partners Capital Management
California
$6.47M -$143K -2,228 -2%
QT
410
Quantbot Technologies
New York
$6.44M +$6M +93,477 +360%
DC
411
Davenport & Co
Virginia
$6.44M +$1.36M +21,149 +22%
TAM
412
Taurus Asset Management
New York
$6.44M +$7.23M +112,510 +1,642%
LMGAM
413
Liberty Mutual Group Asset Management
Massachusetts
$6.42M +$112K +1,739 +1%
QC
414
Quadrature Capital
United Kingdom
$6.41M +$7.64M +118,864 New
SSB
415
Sandy Spring Bank
Maryland
$6.4M +$874K +13,600 +13%
DC
416
Deere & Company
Illinois
$6.38M -$1.46M -22,781 -16%
NB
417
NBT Bank
New York
$6.32M +$11.4K +177 +0.2%
Tudor Investment Corp
418
Tudor Investment Corp
Connecticut
$6.3M +$6.62M +103,087 +747%
PG
419
PEAK6 Group
Illinois
$6.29M +$7.49M +116,649 New
SG Americas Securities
420
SG Americas Securities
New York
$6.27M -$34.1K -531 -0.5%
PMAM
421
Picton Mahoney Asset Management
Ontario, Canada
$6.25M -$19.7M -306,980 -73%
CCM
422
Crossvault Capital Management
Texas
$6.23M +$236K +3,672 +3%
Thrivent Financial for Lutherans
423
Thrivent Financial for Lutherans
Minnesota
$6.2M +$107K +1,660 +1%
FIB
424
First Interstate Bank
Montana
$6.19M +$238K +3,700 +3%
CAN
425
Cetera Advisor Networks
California
$6.14M +$3.06M +47,595 +72%

BMY Hedge Fund Activity: Q3 2016 in Review

1,523 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2016, worth a combined $63.3B — down 30% from $90.9B a quarter earlier.

Sellers outnumbered buyers: 147 funds closed out of BMY and 110 opened new positions — a net loss of 37 holders — while 548 trimmed existing stakes and 663 added.

The largest buyer was Wellington Management Group, adding an estimated $437M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.74B.

  • 1,523 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2016, down from 1,577 in Q2 2016.
  • Funds reported $63.3B of Bristol-Myers Squibb stock for Q3 2016, down 30% quarter-over-quarter.
  • 110 funds opened new Bristol-Myers Squibb positions in Q3 2016 and 147 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q3 2016 was Wellington Management Group, an estimated $437M added.
  • The largest Bristol-Myers Squibb seller in Q3 2016 was T. Rowe Price Associates, an estimated $1.74B sold.

Based on aggregated 13F filings for Q3 2016.